These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2553820)

  • 1. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D.
    Geerligs HJ; Weijer WJ; Welling GW; Welling-Wester S
    J Immunol Methods; 1989 Nov; 124(1):95-102. PubMed ID: 2553820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
    Sanchez-Pescador L; Burke RL; Ott G; Van Nest G
    J Immunol; 1988 Sep; 141(5):1720-7. PubMed ID: 2842401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
    Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
    Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
    Aurelian L; Smith CC; Wachsman M; Paoletti E
    Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines.
    Brynestad K; Babbit B; Huang L; Rouse BT
    J Virol; 1990 Feb; 64(2):680-5. PubMed ID: 2153234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge.
    Eisenberg RJ; Cerini CP; Heilman CJ; Joseph AD; Dietzschold B; Golub E; Long D; Ponce de Leon M; Cohen GH
    J Virol; 1985 Dec; 56(3):1014-7. PubMed ID: 2999419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of purified glycoprotein gB of herpes simplex virus.
    Kino Y; Eto T; Nishiyama K; Ohtomo N; Mori R
    Arch Virol; 1986; 89(1-4):69-80. PubMed ID: 3013134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines.
    Fernández IM; Harmsen M; Benaissa-Trouw BJ; Stuij I; Puyk W; Meloen RH; Snippe H; Kraaijeveld CA
    Vaccine; 1998 Oct; 16(16):1531-6. PubMed ID: 9711800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination by cholera toxin conjugated to a herpes simplex virus type 2 glycoprotein D peptide.
    Drew MD; Estrada-Correa A; Underdown BJ; McDermott MR
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2357-66. PubMed ID: 1383408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel strategy for converting recombinant viral protein into high immunogenic antigen.
    Hinuma S; Hazama M; Mayumi A; Fujisawa Y
    FEBS Lett; 1991 Aug; 288(1-2):138-42. PubMed ID: 1652468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice.
    Geerligs HJ; Kocken CH; Drijfhout JW; Weijer WJ; Bloemhoff W; Wilterdink JB; Welling GW; Welling-Wester S
    J Gen Virol; 1990 Aug; 71 ( Pt 8)():1767-74. PubMed ID: 2167930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies against synthetic peptides of herpes simplex virus type 1 glycoprotein D and their capability to neutralize viral infectivity in vitro.
    Weijer WJ; Drijfhout JW; Geerligs HJ; Bloemhoff W; Feijlbrief M; Bos CA; Hoogerhout P; Kerling KE; Popken-Boer T; Slopsema K
    J Virol; 1988 Feb; 62(2):501-10. PubMed ID: 2826811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.
    Berman PW; Gregory T; Crase D; Lasky LA
    Science; 1985 Mar; 227(4693):1490-2. PubMed ID: 2983428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use.
    Burke RL
    Rev Infect Dis; 1991; 13 Suppl 11():S906-11. PubMed ID: 1664126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody responses and protection in mice immunized with herpes simplex virus type 1 antigen immune-stimulating complex preparations.
    Ertürk M; Jennings R; Hockley D; Potter CW
    J Gen Virol; 1989 Aug; 70 ( Pt 8)():2149-55. PubMed ID: 2769234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of effects of adjuvants on efficacy of virion envelope herpes simplex virus vaccine against labial infection of BALB/c mice.
    Thomson TA; Hilfenhaus J; Moser H; Morahan PS
    Infect Immun; 1983 Aug; 41(2):556-62. PubMed ID: 6307874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses.
    Ugozzoli M; O'Hagan DT; Ott GS
    Immunology; 1998 Apr; 93(4):563-71. PubMed ID: 9659230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
    Bettahi I; Nesburn AB; Yoon S; Zhang X; Mohebbi A; Sue V; Vanderberg A; Wechsler SL; BenMohamed L
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholera toxin conjugates for intragastric vaccination against herpes simplex virus type 2.
    Drew MD; Estrada AE; Underdown BJ; McDermott MR
    Reg Immunol; 1992; 4(2):79-85. PubMed ID: 1503890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.